Il y a eu 50 transactions d'initiés récentes enregistrées pour CytomX Therapeutics, Inc. (CTMX), dont 28 achats et 21 ventes. Le total des achats d'initiés s'élève à $11.82M et le total des ventes d'initiés à $1.95M.
Les initiés notables ayant une activité récente comprennent Mccarthy Sean A., Chu Yu-waye, Ogden Christopher. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — CTMX
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-03-17 |
Mccarthy Sean A. |
CEO |
Vente Informative |
118,969 |
$6.42 |
$764.14K |
1,078,922 |
| 2026-03-17 |
Chu Yu-waye |
Chief Medical Officer |
Vente Informative |
21,279 |
$6.42 |
$136.68K |
189,446 |
| 2026-03-17 |
Ogden Christopher |
Chief Financial Officer |
Vente Informative |
19,323 |
$6.42 |
$124.11K |
296,948 |
| 2026-03-17 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Vente Informative |
31,492 |
$6.42 |
$202.27K |
300,760 |
| 2026-02-02 |
Mccarthy Sean A. |
CEO |
Attribution de RSU |
980,000 |
$6.09 |
$5.97M |
980,000 |
| 2026-02-02 |
Chu Yu-waye |
Chief Medical Officer |
Attribution de RSU |
75,000 |
- |
- |
210,725 |
| 2026-02-02 |
Ogden Christopher |
Chief Financial Officer |
Attribution de RSU |
90,000 |
- |
- |
316,271 |
| 2026-02-02 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Attribution de RSU |
250,000 |
$6.09 |
$1.52M |
250,000 |
| 2026-02-02 |
Lester Rachael |
Chief Business Officer |
Attribution de RSU |
20,000 |
- |
- |
20,000 |
| 2025-11-06 |
Mccarthy Sean A. |
CEO |
Vente Informative |
101,793 |
$4.54 |
$461.91K |
987,891 |
| 2025-10-20 |
Lester Rachael |
Officer |
Inconnu |
- |
- |
- |
- |
| 2025-10-20 |
Lester Rachael |
Chief Business Officer |
Attribution de RSU |
650,000 |
$3.74 |
$2.43M |
650,000 |
| 2025-09-26 |
Mccarthy Sean A. |
CEO |
Attribution de RSU |
285,000 |
- |
- |
285,000 |
| 2025-09-26 |
Chu Yu-waye |
Chief Medical Officer |
Attribution de RSU |
43,750 |
- |
- |
43,750 |
| 2025-09-26 |
Ogden Christopher |
Chief Financial Officer |
Attribution de RSU |
39,150 |
- |
- |
39,150 |
| 2025-09-26 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Attribution de RSU |
18,150 |
- |
- |
18,150 |
| 2025-06-16 |
Mccarthy Sean A. |
CEO |
Vente Informative |
55,511 |
$2.69 |
$149.26K |
1,089,684 |
| 2025-06-16 |
Ogden Christopher |
Chief Financial Officer |
Vente Informative |
10,614 |
$2.69 |
$28.54K |
226,271 |
| 2025-06-16 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Vente Informative |
13,884 |
$2.69 |
$37.33K |
272,252 |
| 2025-06-13 |
Mccarthy Sean A. |
CEO |
Exercice d'Options (Vente) |
150,000 |
- |
- |
- |
| 2025-06-13 |
Ogden Christopher |
Chief Financial Officer |
Exercice d'Options (Vente) |
37,500 |
- |
- |
- |
| 2025-06-13 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Exercice d'Options (Vente) |
37,500 |
- |
- |
- |
| 2025-06-11 |
Jones Elaine V |
Director |
Attribution de RSU |
38,000 |
$2.82 |
$107.16K |
38,000 |
| 2025-06-11 |
Meyers James R |
Director |
Attribution de RSU |
38,000 |
$2.82 |
$107.16K |
38,000 |
| 2025-06-11 |
Gilbert Halley E |
Director |
Attribution de RSU |
38,000 |
$2.82 |
$107.16K |
38,000 |
| 2025-06-11 |
Young Matthew P. |
Director |
Attribution de RSU |
38,000 |
$2.82 |
$107.16K |
38,000 |
| 2025-06-11 |
Mohindru Mani |
Director |
Attribution de RSU |
38,000 |
$2.82 |
$107.16K |
38,000 |
| 2025-06-11 |
Ashworth Alan |
Director |
Attribution de RSU |
38,000 |
$2.82 |
$107.16K |
38,000 |
| 2025-06-11 |
Su Zhen |
Director |
Attribution de RSU |
38,000 |
$2.82 |
$107.16K |
38,000 |
| 2025-03-18 |
Rowland Lloyd A |
General Counsel |
Vente Informative |
10,203 |
$0.60 |
$6.11K |
120,594 |
| 2025-03-18 |
Mccarthy Sean A. |
CEO |
Vente Informative |
37,656 |
$0.60 |
$22.56K |
995,195 |
| 2025-03-18 |
Chu Yu-waye |
Chief Medical Officer |
Vente Informative |
4,025 |
$0.60 |
$2.41K |
135,725 |
| 2025-03-18 |
Ogden Christopher |
Chief Financial Officer |
Vente Informative |
8,551 |
$0.60 |
$5.12K |
201,026 |
| 2025-03-18 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Vente Informative |
19,512 |
$0.60 |
$11.69K |
248,636 |
| 2025-02-04 |
Mccarthy Sean A. |
CEO |
Attribution de RSU |
390,000 |
$0.86 |
$336.96K |
390,000 |
| 2025-02-04 |
Chu Yu-waye |
Chief Medical Officer |
Attribution de RSU |
56,000 |
- |
- |
82,250 |
| 2025-02-04 |
Ogden Christopher |
Chief Financial Officer |
Attribution de RSU |
115,000 |
$0.86 |
$99.36K |
115,000 |
| 2025-02-04 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Attribution de RSU |
115,000 |
$0.86 |
$99.36K |
115,000 |
| 2025-02-04 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Attribution de RSU |
150,000 |
$0.86 |
$129.6K |
150,000 |
| 2024-08-20 |
Rowland Lloyd A |
General Counsel |
Exercice d'Options (Vente) |
11,250 |
- |
- |
- |
| 2024-08-20 |
Mccarthy Sean A. |
CEO |
Exercice d'Options (Vente) |
37,500 |
- |
- |
- |
| 2024-08-20 |
Ogden Christopher |
Chief Financial Officer |
Exercice d'Options (Vente) |
6,875 |
- |
- |
- |
| 2024-08-20 |
Landau Jeffrey B |
Chief Business Officer |
Exercice d'Options (Vente) |
11,250 |
- |
- |
- |
| 2024-08-20 |
Belvin Marcia |
SVP, Chief Scientific Officer |
Exercice d'Options (Vente) |
11,250 |
- |
- |
- |
| 2024-06-12 |
Ogden Christopher |
Chief Financial Officer |
Attribution de RSU |
75,000 |
$1.49 |
$111.75K |
75,000 |
| 2024-05-15 |
Jones Elaine V |
Director |
Attribution de RSU |
38,000 |
$1.96 |
$74.48K |
38,000 |
| 2024-05-15 |
Meyers James R |
Director |
Attribution de RSU |
38,000 |
$1.96 |
$74.48K |
38,000 |
| 2024-05-15 |
Gilbert Halley E |
Director |
Attribution de RSU |
38,000 |
$1.96 |
$74.48K |
38,000 |
| 2024-05-15 |
Young Matthew P. |
Director |
Attribution de RSU |
38,000 |
$1.96 |
$74.48K |
38,000 |
| 2024-05-15 |
Mohindru Mani |
Director |
Attribution de RSU |
38,000 |
$1.98 |
$75.24K |
38,000 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
